← Leaderboards
Andrea Wang-Gillam
Duke University
$3,930,420
Attributed
$7,975,832
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2016–20$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,975,832 · 4
By mechanism
UM1$6,068,118 · 1
P50$1,212,095 · 1
U54$695,619 · 2
Top collaborators
- James L Abbruzzese6 shared
- Elizabeth C Dees6 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- David Reardon$8,732,934
- Michael Barry Kastan$65,974,699
- Manabu Kurokawa$2,396,557
- James L Abbruzzese$10,558,825
Others in their field
Top investigators on “Universities”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$507,483,583
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$463,124,587
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
Research focus
UniversitiesClinical TrialsTumorWashingtonResponseMalignant NeoplasmsFutureInterestResistanceCancer Therapy Evaluation ProgramSignal TransductionBasePathway InteractionsMaintenanceKras2 GeneMalignant Neoplasm Of PancreasChronicMapk1 GeneMutateOrganoidsInhibitor/AntagonistGeneticIn VivoNovel Therapeutics
Grant awards (16)
Project 3: Combination inhibition of ERK for pancreatic cancer treatment$212,596
P50 · FY2020 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,702,907
UM1 · FY2019 · CA
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)$715,167
UM1 · FY2019 · CA
Research Project 2: Development of Synergetic EKR Combinations in PDAC$220,593
U54 · FY2019 · CA · contact PI
Project 3: Combination inhibition of ERK for pancreatic cancer treatment$191,826
P50 · FY2019 · CA · contact PI
Research Project 2: Development of Synergetic EKR Combinations in PDAC$20,073
U54 · FY2019 · CA · contact PI
Research Project 2: Development of Synergetic EKR Combinations in PDAC$20,073
U54 · FY2019 · CA · contact PI
Research Project 2: Development of Synergetic EKR Combinations in PDAC$9,166
U54 · FY2019 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,703,461
UM1 · FY2018 · CA
Project 3: Combination inhibition of ERK for pancreatic cancer treatment$217,154
P50 · FY2018 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$170,500
UM1 · FY2018 · CA
Research Project 2: Development of Synergetic EKR Combinations in PDAC$425,714
U54 · FY2017 · CA · contact PI
Project 3: Combination inhibition of ERK for pancreatic cancer treatment$280,439
P50 · FY2017 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$891,969
UM1 · FY2016 · CA
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$884,114
UM1 · FY2016 · CA
Project 3: Combination inhibition of ERK for pancreatic cancer treatment$310,080
P50 · FY2016 · CA · contact PI